MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
POSTED: September 14, 2022
- Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases
- First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy ...
READ FULL ARTICLE >
MC2 Therapeutics announces breakthrough discovery with the potential to help millions of people suffering from urea associated skin diseases
POSTED: September 1, 2022
- Breakthrough discovery of a novel biological paradigm for treatment of several urea associated skin diseases
- MC2 Therapeutics has patented and initiated development of drug candidates for chronic kidney disease associated pruritus ...
READ FULL ARTICLE >
Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer
POSTED: June 9, 2022
Copenhagen, June 9th 2022 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and ...
READ FULL ARTICLE >
